Sign up today for an exclusive discount along with our 30-day GUARANTEE — Love us or leave, with your money back! Click here to become a part of our growing community and learn how to stop gambling with your investments. We will teach you to BE THE HOUSE — Not the Gambler!

Click here to see some testimonials from our members!

Gilead Volatile After Kite Pharma’s Yescarta Gets FDA Approval

Courtesy of Benzinga.

Gilead Sciences, Inc. (NASDAQ: GILD) shares are trading higher by 80 cents (1 percent) at $80.81 in Thursday’s session.

After Wednesday’s close, subsidiary Kite Pharma announced FDA approval for Yescarta, a gene-altering treatment for cancer.

After a higher open, Gilead continued in that direction before finally peaking at $82.47 and reversed course. That high comes just under its Oct. 12 high ($82.82).

The stock has come hard off that level and so far found intraday support just under the upper-range of Wednesday’s ($80.84) as $80.52 stands as the low for the session as of 10:30 a.m. EST.

Posted-In: Technicals Intraday Update Movers Trading Ideas


Do you know someone who would benefit from this information? We can send your friend a strictly confidential, one-time email telling them about this information. Your privacy and your friend's privacy is your business... no spam! Click here and tell a friend!





You must be logged in to make a comment.
You can sign up for a membership or get a FREE Daily News membership or log in

Sign up today for an exclusive discount along with our 30-day GUARANTEE — Love us or leave, with your money back! Click here to become a part of our growing community and learn how to stop gambling with your investments. We will teach you to BE THE HOUSE — Not the Gambler!

Click here to see some testimonials from our members!